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Metode analisis spektrofluorometrik yang sederhana, sensitif, cepat, dan murah 
berdasarkan efek pemadaman fluoresensi pada ion-kompleks yang dibentuk oleh eritrosin 
dan deksklorfeniramin maleat. Parameter eksperimental yang mempengaruhi reaksi 
dioptimalkan. Metode yang diusulkan selanjutnya divalidasi dan diterapkan untuk analisis 
deksklorfeniramin pada tablet komersial. Intensitas fluoresensi direkam pada 556 nm setelah 
eksitasi pada 504 nm. Pemadaman fluoresensi optimal pada kondisi buffer pH < 4,4 dengan 
waktu reaksi 10 menit serta sebanding dengan konsentrasi (0,3-8,0 ppm) dengan LoD 0,4 
ppm dan LoQ 1,3 ppm. 





FLUORESCENCE QUENCHING EFFECT OF DEXCHLORPHENIRAMINE 
MALEATE-ERYTHROSINE SYSTEM. In this study, a simple, sensitive, rapid, and low-
cost spectrofluorometric method based on fluorescence quenching effect on the ion-pair 
complexation formed by erythrosine and dexchlorpheniramine maleate is proposed for the 
determination of the drug. The experimental parameters that affect the reaction are 
optimized. The proposed method was further validated and applied for dexchlorpheniramine 
analysis on commercial tablets. Fluorescence intensity was recorded at 556 nm after 
excitation at 504 nm. Fluorescence quenching strength was optimal at pH <4.4 buffer 
conditions with a reaction time of 10 minutes and was proportional to concentration (0.3-
8.0 ppm) with LoD of 0.4 ppm and LoQ of 1.3 ppm.  




Dexchlorpheniramine is pharmacologically active as a dextrorotatory enantiomer of 
chlorpheniramine typically used in the form of maleate salt [1]. It belongs to an antihistamine 
group affecting H1 receptors to decrease the allergic reactions [2]. DXC is significantly 
impair driving performance after both one-time and daily administration due to the ability  
crossing the blood-brain barrier that may cause sedation [3]. The development of medication 
formulations containing active Dexchlorpheniramine maleate (DXC) and excipients is 
critical for correct DXC activity. Some methods were successfully established in order to 
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DXC determination [4][5][6]. It is commonly acknowledged that chromatographic methods 
need vast volumes of hazardous organic solvents, laborious operations, sometimes 
necessitate expensive detectors, and take a lot of time. Unlike GC and HPLC, the 
spectrofluorometer is easy and economical to use. Our purpose in developing a novel method 
for the assay of DXC comes from its importance and wide availability for treating different 
allergy symptoms [1] as well as its sedative impact, which can impair cognitive functions 
such as driving performance. 
Erythrosine B (ERB) (Figure 1a) primarily used for food dyeing and was successfully 
used for spectrofluorimetric determination of some non-sedating antihistamines [7] and 
proteins determination [8]. 
(a)      (b)  
Figure 1. Structure of (a) Erythrosine, (b) Dexchlorpheniramine maleate. 
In this study, it was observed that DXC has a quenching effect on the fluorescence 
intensity of ERB through the formation of ion-pair complexes with ERB, which is measured 
spectrofluorimetrically without solvent extraction. The linear ranges of calibration curves 
for the determination of DXC were 0.3–8.0 µg/mL. The proposed method provides a fast 
and sensitive procedure for the analysis of the DXC. The featured method is a low-cost 
technique for assessing the examined substances in quality control laboratories, which is 
particularly useful when cost is a major consideration. Erythrosine B chosen as reagent is 
commercially accessible that most ordinary analytical laboratories can purchase. 
 
Material and Methods 
Fluorescence emission were carried out using Spectrofluorometer Shimadzu RF-6000 
(Kyoto, Japan) with 1 cm quartz cell, pH meter Senz (Singapore). Erythrosine B (Sigma, 
CAS number 16423-68-0), distilled water, sodium hydroxide, acetic acid, and phosphoric 
acid were analytical grades. Dexchlorpheniramine maleate was purchased from the National 
Agency of Drug and Food Control of Indonesia (Jakarta, Indonesia), Commercial tablets 
Poloforr® were obtained from local pharmacy.  
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Britton-Robinson (BR) buffer solution preparation done by diluting 1,143 g NaOH and 
0,884 g H3BO3 with 300 mL water, a 0.830 mL of 85% CH3COOH and 0,990 mL phosphoric 
acid then mixed thoroughly to the mixture, and the volume was fixed to 500 mL with water. 
Adjustment of pH (3,6-5,7) was made by adding hydrochloric acid (37%). 
ERB 175 µg/mL and DXC 100 µg/mL were used as stock solutions. A 2,0 mL ERB 
was pipetted into a volumetric flask, added 1.5 mL BR buffer solution and suitable mounts 
of DXC (0,3; 1,0; 2,0; 3,0; 5,0; 8,0 µg/mL). The mixture was then diluted to 10 mL with 
water, well mixed, and set aside for 10 min. The fluorescence spectra were recorded at 200-
800 nm after excitation at 504 nm. 
 
Results and Discussion 
Characteristics of the Spectra 
Erythrosine is highly fluorescent in nature and providing fluorescence spectra. The 
optimum excitation and emission wavelengths were obtained from 3D fluorescence spectra 
of freshly prepared erythrosine B solution. The stability of erythrosine B solution in distilled 
water was first checked by measuring fluorescence spectrum at zero time after dilution and 
then observed every 15 minutes gap. Erythrosine B provided emission wavelength at 556 
nm and whereas the excitation wavelength at 504 nm (Fig. 2). The emission intensity of the 
erythrosine B solution was stable after preparation, but there was a minor decrease in 
emission intensity at two hours (Figure. 2). So, it is recommended to use erythrosine solution 
as a probe at maximum of 2 hours after dilution.  
 
Figure 2. three dimensional intensity scan of eritrosin B diluted in water 
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Figure 3. Fluorescence emission intensity of Erythrosine 128×10−7 mol/L in water solution 
(a) freshly made, and (b) at 2 hour.  
 
Dexchlorpheniramine maleate itself has no fluorescence, but Erythrosine has 
fluorescence. After DXC mixed with ERB, the spectra of ERB and ERB-DXC were scanned 
with spectrofluorometer. As shown in Figure 2, the peak of emission intensity of ERB (λem 
=554nm) was decreased but not shifted. Thus, the result shown that ERB and DXC reacted 
and resulting in new complex formation.  
 
Figure 4. Fluorescence spectra of (a) ERB 128×10−7 mol/L; and (b) ERB-DXC (128×10−7 
mol/L -128×10−7 mol/L) in water without buffer addition. While (c) ERB 128×10−7;(d) 
DXC  128×10−7 mol/L in in the presence of 1,5 mL Britton-Robinson buffer of pH 3,6;.  
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Figure 5. Fluoroscence spectra of (a) ERB 35 µg mL-1 , and (b) 0,03 mL, (c) 0,075 mL, (d) 
0,1 mL; (e) 0,2 mL; (f) 0,3 mL (g) 0,5 mL, (h) 0,8 mL of 100 µg mL-1 of DXC. A 1,5 mL 
Britton Robinson buffer of pH 3,6 was added to every single solution and made up to 10 
mL with water. 
 
Figure 6. Fluoroscence spectra of ERB 35 µg mL-1 and 3 µg mL-1 of DXC in the (a) 
absence and (b) prescence of 1,5 mL Britton Robinson buffer of pH 5,0; (c) 4,5; (d) 4,3; (e) 
4,1; (f) 3,6. Each solution made up to 10 mL with water. 
Reasons of fluorescence quenching  
Erythrosine itself provide emission without any addition of buffer or studied drug 
(Figure 2). The fluorescence of ERB (λem =556) was decreased when Dexchlorpheniramine 
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maleate was added into ERB solution. The fluorescence emission peak did not shift, which 
showed that the ion complex were formed. Fluorescence quenching is resulted from the 
formation of ion-complexes which led to decrease of free ERB concentration. While in acidic 
solution, the quenching effect is more visible due to preferred ionization of ERB.  
The stoichiometry of erythrosine B-dexchlorpheniramine complex was studied by 
mole ratio method. It was done by combining different volumes of 2,558 × 10-6 M 
dexchlorpheniramine maleate (0,3–0,8 mL) with 0.5 mL of 2,558 × 10-6 M erythrosine B in 
the presence of Britton-Robinson buffer solution (pH 3,6). The reduction in fluorescence 
intensity of erythrosine B was recorded at 556 nm after constant excitation (504 nm). The 
ratio of F0/F was plotted (Figure. 6) against to mole ratio of dexchlorpheniramine maleate 
and erythrosine B. The strongest quenching was reached with 0,5 mL of 2,558 × 10−6 M 
dexchlorpheniramine maleate reacted with 0,5 mL of 2,558 × 10−6 M erythrosine B, as 
shown in the figure 7. The stoichiometry provided by this reaction was 1 mol of 
dexchlorpheniramine maleate coupled with 1 mol of erythrosine B. 
Determination of proper reaction time done by monitoring the emission intensity 
from 0 minute to 60 minute after the mixture was made. As shown in Figure. 7, stability of 
the emission intensity was at 10-15 minutes after the mixture was made. 
 
Linearity 
The determination of linearity was done either by plotting fluorescence ratio against 
concentration or from linear regression equation F0/F = bC+ a, where F0 stand for the 
fluorescence intensities of erythrosine B observed in the existence dexchlorpheniramine 
maleate and F is the emission intensity after DXC addition. While b is the slope, a is the 
intercept, and C is the dexchlorpheniramine maleate concentrations (µg/mL). Table 1 shows 
the linear regression equation of the proposed method, where limit of detection and limit of 
quantitation is derived from the generated equation. The Pearson correlation coefficients 
ranged from 0,995 to 0,999, confirming that the results was linear. 
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Figure 7. Calibration curve of ERB-DXC mixture 



























































 Limit of Detection and Limit of Quantification 
Respectively, LOD and LOQ were 3 σ/b and 10 σ/b, both are derived from linear 
regression equation, where σ is the standard deviation of the F0/F-intercept and b is the slope 
of the calibration curve. Under the defined experimental environments, standard calibration 
curves for DXC with erythrosine B were constructed by plotting DXC concentration against 
the fluorescence quenching value (Figure 5). 
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Replicated analysis of three separate solutions of DXC at three different 
concentration levels: 80% (1,6 mg), 100% (2 mg), and 120% (2,4 mg) were studied to 
determine intra-day precision of the proposed method. This experiment (n = 6) was repeated 
for three consecutive days to determine the inter-day precision. RSD% values for DXC for 
intra-day were ranged from 0,42 to 1,74 indicating good repeatability.  
Table 2. RSD of three different concentration levels of DXC added to ERB 
 80% (mg) 100% (mg) 120% (mg) 
N1 1,58 1,96 2,37 
N2 1,57 1,98 2,36 
N3 1,63 1,96 2,36 
N4 1,60 1,97 2,43 
N5 1,64 1,97 2,41 
N6 1,60 1,98 2,41 
Average 1,60 1,97 2,39 
SD 0,03 0,01 0,03 
RSD (%) 1,74 0,42 1,29 
 
Accuracy 
Three different levels of DXC concentrations (1,6; 2,0; and 2,4 mg) were consisted 
30% from the DXC stock solution and 70% DXC from tablet powder. The samples analyzed 
(n = 6) to determine the accuracy of the proposed method. Accuracy was determined by 
comparing measured concentrations of DXC stock solution added with the actual values. 
The accuracy of the proposed method for the studied drugs ranged from 95,01% to 100,35% 
(Table 3.) representing good accuracy of the proposed method. Either obtained accuracy and 
precision value were fit for measurements of quality control. 
1.1.Robustness 
The robustness of the proposed method was determined by studying the minor 
changes (pH value and the volume of buffer added) from optimized condition affecting the 
accuracy. Results are shown in Table 4. It was found that none of these variables had a 
significant effect on the accuracy delivers a sign of the reliability of the proposed method 
during the normal usage, so the proposed method is considered robust. 
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Table 3. Recovery (%) of the proposed method 
   n 1,6 mg 2 mg 2,4 mg 
1 95,53 93,38 95,10 
2 93,19 96,17 94,60 
3 106,10 93,20 93,75 
4 99,00 95,46 103,83 
5 108,00 95,60 101,24 










Table 4. Robustness of the developed method 
Kondisi *Recovery±SD RSD 
**Normal 95,01 ±1,37 1,44 


















  * Average recovery from 6 replicates  
** Optimized condition: ERB 35ppm, DXC 2 ppm, 1,5 mL buffer BR pH 3,6 at total 
volume 10 mL with distilled water 
 
Determination of DXC in tablet dosage form 
A total of 571.21 mg of tablet powder equivalent to 6 mg of dexchlorpheniramine 
maleate was dissolved in distilled water up to 50 mL. The solution was homogenized and 
filtered using a 0.4 m disc filter to separate the residue from the drug excipient. The filtrate 
was then taken 0.5 mL and added to a 10 mL volumetric flask filled with 2 mL of 175 ppm 
erythrosine and 1.5 mL of pH 3.6 buffer and filled with distilled water to the mark. 
Calculation of the levels of dexchlorpheniramine maleate in the sample was determined 
based on linear regression obtained in the linearity stage. 
The concentration of dexchlorpheniramine maleate as an active substance in 
pharmaceutical preparations in tablet form required in the Indonesian Pharmacopoeia is 
90.0-110% of the levels claimed in the label. The proposed analytical method obtains an 
average level of 95.6% from 6 repetitions (Table 5.). It is concluded that the levels of active 
substances in the pharmaceutical preparation samples have met the pharmacopoeial 
standards. The type of liquid chromatography-mass spectroscopy (LC-MS) analysis method 
is reported to be used as a trace determination method of dexchlorpheniramine maleate in 
human plasma samples [4]. The time required for analysis using LC-MS for each sample 
takes 6 minutes with extraction using ethyl acetate. The stratified extraction to obtain 
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dexchlorpheniramine maleate was also carried out on the uv-vis spectrophotometric analysis 
listed in the Indonesian Pharmacopoeia monograph. 
Table 5. Assay of DXC in commercial tablet 
n 
DXC assay measured 
(mg) 
% to label 
1 1,895 94,797 
2 1,892 94,615 
3 1,916 95,808 
4 1,939 96,978 
5 1,918 95,940 









Dexchlorpheniramine maleate can be determined by fluorescence spectrophotometry 
with erythrosine B as a probe. Dexchlorpheniramine maleate reacts with erythrosine B to 
form an ion complex, leading to fluorescence quenching of erythrosine B. 
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